Sign inJoin waitlistJoin the waitlist

Jay-Jiguang Zhu

Professor and Director, Neuro-Oncology · University of Texas Health Science Center at Houston

Credentials: · · · · ·

History

University of Texas Health Science Center at Houston
Present

Massachusetts General Hospital
2005–2006
Harvard Medical School Dana-Farber Cancer Center
2004–2005
Neurology
Tufts University School of Medicine
2000–2003
Berkshire Medical Center
1999–2000
State University of New York
MCGILL UNIV, MONTREAL
1995–1999

Research

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
JAMA · 2017 · 2,133 citations
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial
JAMA · 2015 · 1,013 citations
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
Clinical Cancer Research · 2019 · 237 citations

Leomar Ballester
23 papers · 6 as a fellow
Nitin Tandon
23 papers
Sigmund Hsu
14 papers
Angel Blanco
12 papers
MB
Meenakshi Bhattacharjee
12 papers
Julian Wu
8 papers
Mark Amsbaugh
8 papers
PB
Peter Black
8 papers
Arash Kamali
6 papers
Kamand Khalaj
4 papers · 3 as a resident
Anusha Gandhi
3 papers · 1 as a resident
Arthur Day
3 papers

Clinical trials

A Prospective Study of a Modified Lumbar Puncture (LP) Procedure That Reduces Post-Lumbar Puncture Headaches (PLPH) in Patients
Principal investigator · Recruiting
The University of Texas Health Science Center, Houston
2023–2026
A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma
Principal investigator · Unknown · Phase 1, Phase 2
TransMolecular
2008–2010
131-I-TM-601 Study in Adults With Solid Tumors
Principal investigator · Completed · Phase 1
TransMolecular
2006–2008
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Site PI · Recruiting · Phase 2
Alliance for Clinical Trials in Oncology
2015–2028